Goldline Pharmaceutical IPO Listing Today 19 May 2026: 2026 Most Subscribed SME IPO at 841x Debuts on BSE SME — Opened at Rs 59.87, Trades at Rs 56.77 (+32%)

The Goldline Pharmaceutical IPO listing takes place today at 10 AM on BSE SME, 19 May 2026. The Rs 11.61 crore issue attracted bids worth over Rs 9,800 crore — 840.74 times the issue size — making it the most oversubscribed SME IPO of 2026 so far, per News9Live. The NII category was subscribed an extraordinary 1,662.04 times, retail 881.15 times and QIBs 180.22 times. The stock opened at approximately Rs 59.87 on BSE SME at 9:40 AM, a 39.2 percent premium over the Rs 43 issue price. It then dropped sharply to Rs 56.66 by 11:50 AM as anticipated NII selling pressure hit. The stock has since stabilised and is currently trading at Rs 56.77, up Rs 13.77 or 32.02 percent from the issue price.

Goldline Pharmaceutical IPO Listing: Complete Data

• Listing Date: 19 May 2026 (Today, 10 AM on BSE SME)
• Issue Price (Upper Band): Rs 43 per share
• Price Band: Rs 41 to Rs 43 per share
• Issue Size: Rs 11.61 crore (27 lakh shares, 100% fresh issue)
• Final Overall Subscription: 840.74 times — 2026’s most subscribed SME IPO
• NII Subscription: 1,662.04 times
• Retail Subscription: 881.15 times
• QIB Subscription: 180.22 times
• GMP (14 May daytime peak): Rs 25 (58.14% premium, implied Rs 68)
• GMP (14 May late night, pre-listing final): Rs 15 (34.88% premium, implied Rs 58)
• Actual Opening Price: Rs 59.87 (39.2% premium over issue price of Rs 43)
• Registrar: Bigshare Services Pvt Ltd
• Market Maker: Nirman Share Brokers Pvt Ltd
• Current Trading Price: Rs 56.77 (+Rs 13.77, +32.02% from issue price) — trading flat since 11:50 AM
• CMD: Amol Laxmikant Mujumdar

Track Goldline Pharmaceutical live listing price on BSE SME on the Check the Univest Screener for live data.

Actual Listing: Opened at Rs 59.87, Corrected to Rs 56.77 (+32%) — How It Played Out

The Goldline Pharmaceutical IPO opened at approximately Rs 59.87 on BSE SME at 9:40 AM on 19 May 2026, a 39.2 percent premium over the Rs 43 issue price. This is slightly above the GMP-implied Rs 58 (Rs 15 final GMP), validating the grey market’s pre-listing estimate. The opening was stronger than the settled GMP suggested, demonstrating genuine demand at listing from non-allotted investors trying to buy from the open market.

However, the sharp intraday decline from Rs 59.87 to Rs 56.66 between 9:40 AM and 11:50 AM played out exactly as predicted. The 1,662x NII oversubscription meant thousands of HNIs received tiny proportionate allotments and sold immediately at opening to recover small gains. This created a wall of selling in the first two hours. The stock has since found support and is trading flat at Rs 56.66 to Rs 56.77, up a strong 32.02 percent from the Rs 43 issue price.

Tap to Access Best Research Pieces on Univest

840x Subscription Breakdown: What Each Category Means

NII at 1,662x — Record HNI Demand, But Small Allotments

The NII subscription of 1,662.04 times is the critical number to understand for Goldline Pharmaceutical IPO listing day dynamics. At 1,662x oversubscription in the NII category, HNIs receive a proportionate allotment of approximately 1/1,662 of their applied quantity. An HNI who applied the minimum 3 lots (Rs 3.87 lakh) receives approximately 5.42 shares — worth about Rs 233 at the issue price. At Rs 58 listing, this amounts to Rs 314. This means most NII allottees will immediately sell their small proportionate allocations, creating heavy selling pressure in the first 30 to 60 minutes of Goldline Pharmaceutical IPO listing trade.

Retail at 881x — Lottery Winners Have Strong Gains

The retail subscription of 881.15 times means 1 in 881 retail investors who applied received allotment of exactly 1 lot (6,000 shares) via computerised lottery. At the Rs 43 issue price, this allotment cost Rs 2,58,000. At the Rs 58 expected listing price, these 6,000 shares would be worth Rs 3,48,000 — a potential gain of Rs 90,000 (34.88% return on issue price). Unlike NII allottees, retail winners received a meaningful full-lot allotment and have stronger motivation to either sell at the opening for a Rs 90,000 gain or hold for further upside.

QIB at 180x — Institutional Support Post-Listing

QIB subscription at 180.22 times is the most constructive long-term signal. Institutional investors (mutual funds, banks) assessed Goldline’s 10.48x PE at a steep discount to industry 13-15x and subscribed heavily. Post-listing, QIB allottees typically hold positions and accumulate further from the open market rather than selling at opening prices, providing medium-term price support for the Goldline Pharmaceutical IPO listing.

About Goldline Pharmaceutical: The Company Making Its BSE SME Debut

Goldline Pharmaceutical Limited, incorporated in August 2004 in Nagpur, Maharashtra, is an asset-light pharmaceutical marketing company with zero owned manufacturing. Products are made by 15 third-party contract manufacturers per Goldline’s specifications and sold under the Goldline brand across 7 states.

• 5 Brand Divisions: Goldline Pharma (42 products — physicians, orthopaedics, ENT, surgery, neurology, gastroenterology), Cardinal (54 products — cardiology, diabetology), Aayushman (18 products — paediatrics), InLife (22 products — critical care, ICU), Wellness (10 products — cancer support)
• FY25 Revenue: Rs 28.06 crore (+19% YoY) | FY24: Rs 23.57 crore | FY23: Rs 19 crore
• FY25 PAT: Rs 2.83 crore (+56.4% YoY from Rs 1.81 crore)
• ROE: 27.34% — highest among listed pharma marketing comparables
• PE at Issue Price: 10.48x — vs listed peers at 13 to 15x (significant discount)
• Geography: Maharashtra (44% revenue), MP, Odisha, Jharkhand, Tamil Nadu, Rajasthan, Bihar
• IPO Proceeds: Debt repayment Rs 8.35 crore + general corporate purposes

Hold or Sell: Listing Day Strategy for Allotted Investors

For Retail Investors (1 Lot = 6,000 Shares at Rs 43)

The stock opened at Rs 59.87 and has since corrected to Rs 56.77 (+32.02%). For retail allottees who have not yet sold: the stock is currently at Rs 56.77 giving a gain of Rs 13.77 per share (Rs 82,620 on 6,000 shares). The opening Rs 59.87 gave an opportunity for Rs 1,00,620 gain. Those who sold at the open captured the maximum gain. At the current price of Rs 56.77, it still represents a 32 percent return on issue price — selling now is still a strong outcome for listing-gain investors.

For long-term holders who believe in Goldline’s pharma marketing growth story: keep holding with a target of Rs 70 to Rs 80 over 12 months. The 10.48x PE vs 13-15x industry average and 27.34% ROE justify a medium-term re-rating toward industry multiple.

For Investors Who Did Not Receive Allotment

Investors who did not receive allotment: the predicted NII selling pressure has already occurred. The stock dropped from Rs 59.87 to Rs 56.66 and is now flat. If it dips toward Rs 54 to Rs 55 in subsequent sessions, that presents a secondary entry opportunity at a slight discount to current levels. Do not chase at Rs 56.77 if it has already run from the open — wait for a pullback.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces on Goldline Pharmaceutical live listing price, buy-sell data and BSE SME tracking!

Key Risks at the Goldline Pharmaceutical IPO Listing

• NII Selling Pressure: 1,662x NII subscription means tens of thousands of HNIs received tiny proportionate allotments and will sell immediately, creating heavy early selling pressure.
• GMP Retreat: GMP declined from Rs 25 to Rs 15 between Day 3 daytime and listing eve, suggesting grey market participants see Rs 58 not Rs 68 as realistic.
• Weak Macro: Nifty is under pressure from crude above $109 and rupee at 96.17. A weak index can cap even a strong listing.
• Related-Party Revenue: 22% of revenue from promoter-related entities is a long-term governance risk.
• SME Liquidity: Post-listing BSE SME volumes are thin. Price swings can be sharp with limited float.

Conclusion

The Goldline Pharmaceutical IPO listing today on 19 May 2026 is the most anticipated BSE SME debut of May 2026 after 840.74 times overall subscription, including an extraordinary 1,662x NII and 881x retail demand. The final GMP of Rs 15 (after peaking at Rs 25) implies an expected opening price of approximately Rs 58, a 34.88 percent gain over the Rs 43 issue price. The stock opened at Rs 59.87 (39.2% premium) and has corrected to Rs 56.77 (+32.02%) following NII selling pressure exactly as predicted. Retail allottees who sold at open captured Rs 1,00,620 gain per lot. Those still holding can target Rs 65 to Rs 70 medium-term. Long-term investors can hold for Rs 70 to Rs 80 over 12 months. Track the live Goldline Pharmaceutical IPO listing price from 10 AM on BSE SME on Univest. Consult a SEBI-registered advisor before any listing-day decision.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

FAQs on Goldline Pharmaceutical IPO Listing Today

What is the expected Goldline Pharmaceutical IPO listing price today?

Ans. The Goldline Pharmaceutical IPO opened at approximately Rs 59.87 on BSE SME at 9:40 AM on 19 May 2026, a 39.2 percent premium over the Rs 43 issue price — slightly above the Rs 58 final GMP implied price. The stock dropped to Rs 56.66 on NII selling pressure and is currently trading at Rs 56.77, up 32.02 percent from the issue price. Track the live price on BSE SME via the Univest Screener.

What was the final Goldline Pharmaceutical IPO subscription?

Ans. The Goldline Pharmaceutical IPO was subscribed 840.74 times the issue size — 2026’s most oversubscribed SME IPO. NII subscribed 1,662.04 times, retail 881.15 times and QIBs 180.22 times. Total bids attracted were approximately 840.74 times the 19.68 lakh shares on offer, equivalent to approximately Rs 9,800 crore in applications for a Rs 11.61 crore issue.

Should I buy Goldline Pharmaceutical on the listing day from the market?

Ans. Investors who missed allotment should NOT chase the opening price at Rs 58. With 1,662x NII oversubscription creating heavy selling pressure in the first 30 to 60 minutes, the stock may dip to Rs 52 to Rs 55 before finding a floor. Wait for the initial selling pressure to clear before considering buying the Goldline Pharmaceutical IPO listing from the open market.

Why did the Goldline Pharmaceutical GMP fall from Rs 25 to Rs 15?

Ans. The GMP peaked at Rs 25 during the Day 3 subscription close on 14 May as speculative grey market demand intensified. Once the subscription window closed, the GMP settled at Rs 15 (Rs 58 implied listing). At the actual listing, the stock opened at Rs 59.87 — slightly above the GMP-implied Rs 58 — confirming the grey market estimate was accurate. The post-open correction to Rs 56.77 reflects the NII selling pressure from 1,662x oversubscription, which was fully anticipated in pre-listing analysis.